文献速递心境障碍

氯胺酮-心理治疗随机临床试验:难治性抑郁的致幻剂模型治疗

The Music for Subanesthetic Infusions of Ketamine randomised clinical trial: ketamine as a psychedelic treatment for highly refractory depression.
PubMed 文献 · Br J Psychiatry · 2025-06-18

结果显示两组在4周时抑郁、焦虑和自杀意念均显著改善且8周随访维持,致幻样体验在两组间无差异,神秘体验可能是氯胺酮抗抑郁作用的中介机制。

要点

  • 氯胺酮-心理治疗对重度难治性抑郁有显著且持续的抗抑郁、抗焦虑和抗自杀效果。
  • 给药期间是否播放音乐不影响治疗效果或致幻体验强度。
  • 神秘样体验与氯胺酮的即时和持续精神获益相关。

核心结论

  • 氯胺酮-心理治疗对重度难治性抑郁具有显著且持续至8周随访的获益,无论是否联合音乐。
  • 氯胺酮产生的致幻体验强度与裸盖菇素相当,神秘样体验可能是其即时和持续精神获益的机制。

研究设计与样本

  • 两中心、单盲随机临床试验(NCT04701866),于2021年1月至2022年8月在加拿大蒙特利尔开展。
  • 干预为4周内6次亚麻醉剂量氯胺酮输注联合心理支持,随机分配在给药期间接受音乐或匹配的非音乐支持。
  • 主要疗效结局为盲法评定的蒙哥马利-奥斯伯格抑郁评定量表,并探索致幻样体验及其与抑郁的逐次关系。

主要发现

  • 音乐组与非音乐组在治疗效果和致幻体验上无差异。
  • 两组在4周时临床评定和自我报告的抑郁均显著下降(d=1.2和d=0.87;p<0.001)。
  • 两组在4周时焦虑(d=0.8,p<0.001)和自杀意念(d=0.4,p<0.05)均显著下降,且8周随访完全维持。
  • 氯胺酮体验具有高度情感性和神秘性,聚合分析支持神秘样体验作为抗抑郁作用机制。

关键数值与推荐

  • 主要疗效指标为蒙哥马利-奥斯伯格抑郁评定量表,由盲法评定者评估。
  • 致幻样体验采用神秘体验问卷和情感突破量表评估。
  • 抑郁与体验的逐次关系采用多层、时间滞后协变量模型(含自回归残差)探索。

临床怎么用

  • 对于重度难治性抑郁,可考虑氯胺酮-心理治疗(6次亚麻醉剂量输注联合心理支持)作为治疗选择。
  • 治疗中无需强制联合音乐,因音乐未显示额外获益。
  • 应关注患者的神秘样体验,其可能预示更好的即时和持续疗效。

局限性

  • 单盲设计,患者对音乐分组无法设盲。
  • 研究在加拿大两中心开展,外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ketamine exerts potent but transient antidepressant effects in treatment-resistant depression (TRD). Combinations of ketamine and psychotherapy have attracted interest, but no trial has investigated a psychedelic model of ketamine-psychotherapy for TRD to our knowledge. AIMS: This secondary analysis of a randomised clinical trial (RCT) explores the therapeutic effects and experiential mechanisms of the Montreal Model of ketamine-psychotherapy for TRD, with or without music. METHOD: A two-centre, single-blinded, RCT conducted in Montreal, Canada, between January 2021 and August 2022 (NCT04701866). Participants received ketamine-psychotherapy for TRD - six subanaesthetic infusions over 4 weeks and psychological support - with either music or matched non-music support during ketamine doses, as per random group assignments. The primary therapeutic outcome was the Montgomery-Åsberg Depression Rating Scale, assessed by blinded raters. Psychedelic-like experiences, evaluated by the Mystical Experience Questionnaire and Emotional Breakthrough Inventory, and their session-by-session relationships with depression were explored with multilevel, time-lagged covariate models with autoregressive residuals. RESULTS: Thirty-two participants with severe and highly comorbid TRD, including high rates of personality disorder and suicidality, received 181 ketamine infusions. Therapeutic outcomes and psychedelic experiences did not differ between music (n = 15) and non-music (n = 17) interventions. Both groups experienced significant reductions in clinician-rated and self-reported depression (d = 1.2 and d = 0.87, respectively; p < 0.001), anxiety (d = 0.8, p < 0.001) and suicidality (d = 0.4, p < 0.05) at 4 weeks, fully maintained at 8-week follow-up. Ketamine experiences were highly emotional and mystical. Converging analyses supported mystical-like ketamine experiences as mechanisms of its antidepressant effects. CONCLUSIONS: This trial found large and notably sustained benefits of ketamine-psychotherapy for severe TRD, with or without music, and psychedelic experiences of comparable intensity to those observed with psilocybin. Mystical-like experiences may particularly contribute to ketamine's immediate and persistent psychiatric benefits.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Greenway KT, Garel N, Dinh-Williams LL, et al. The Music for Subanesthetic Infusions of Ketamine randomised clinical trial: ketamine as a psychedelic treatment for highly refractory depression. Br J Psychiatry. 2025. PMID: 40528492. doi:10.1192/bjp.2025.102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。